ProCE Banner Activity

A Quick Guide to Bispecific Antibodies for the Treatment of Relapsed/Refractory Multiple Myeloma

Clinical Thought

Read my thoughts on a few key questions addressing the role of bispecific antibodies in treatment and considerations with implementing them into the care of patients with relapsed/refractory multiple myeloma.

Released: September 24, 2024

Expiration: September 23, 2025

Share

Faculty

Caitlin Costello

Caitlin Costello, MD

Clinical Professor of Medicine
Director, Multiple Myeloma Program
Division of Blood and Marrow Transplantation
Moores Cancer Center
UC San Diego
La Jolla, California

Provided by

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Supported by a grant from Pfizer Inc. Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pfizer, Inc.

Regeneron Pharmaceuticals, Inc

Partners

Clinical Care Options, LLC

ProCE Banner

Disclosure

Primary Author

Caitlin Costello, MD

Clinical Professor of Medicine
Director, Multiple Myeloma Program
Division of Blood and Marrow Transplantation
Moores Cancer Center
UC San Diego
La Jolla, California

Caitlin Costello, MD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Genentech, Janssen, Karyopharm, Pfizer.